Details of the Drug

General Information of Drug (ID: DMGL19D)

Drug Name
Enzalutamide
Synonyms MDV3100; Enzalutamide (AR inhibitor)
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [1]
Drug Type
Small molecular drug
Sequence
5'-CTCCAACATCAAGGAAGATGGCATTTCTAG
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 464.4
Topological Polar Surface Area (xlogp) 3.6
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 5.8 days (in patients) [2]
Metabolism
The drug is metabolized via the hepatic [3]
Vd
The volume of distribution (Vd) of drug is 110 L [4]
Chemical Identifiers
Formula
C21H16F4N4O2S
IUPAC Name
4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
Canonical SMILES
CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI
InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
InChIKey
WXCXUHSOUPDCQV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
15951529
ChEBI ID
CHEBI:68534
CAS Number
915087-33-1
DrugBank ID
DB08899
TTD ID
D0QK5X
ACDINA ID
D01051

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Prostate cancer
ICD Disease Classification 2C82.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Androgen receptor (AR) DTT AR 2.13E-01 -0.07 -0.11
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Enzalutamide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Darolutamide DMV7YFT Major Increased metabolism of Enzalutamide caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [16]
Coadministration of a Drug Treating the Disease Different from Enzalutamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Accelerated clearance of Enzalutamide due to the transporter induction by Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [17]
Ivosidenib DM8S6T7 Major Increased metabolism of Enzalutamide caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [18]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Enzalutamide and Gilteritinib. Acute myeloid leukaemia [2A60] [17]
Oliceridine DM6MDCF Major Increased metabolism of Enzalutamide caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [19]
Ivabradine DM0L594 Major Increased metabolism of Enzalutamide caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Major Increased metabolism of Enzalutamide caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [17]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Enzalutamide and Levalbuterol. Asthma [CA23] [20]
ABT-492 DMJFD2I Moderate Accelerated clearance of Enzalutamide due to the transporter induction by ABT-492. Bacterial infection [1A00-1C4Z] [21]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Enzalutamide caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Erdafitinib DMI782S Major Increased metabolism of Enzalutamide caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [23]
Pexidartinib DMS2J0Z Major Decreased metabolism of Enzalutamide caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [24]
HKI-272 DM6QOVN Major Increased metabolism of Enzalutamide caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
LY2835219 DM93VBZ Major Increased metabolism of Enzalutamide caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Enzalutamide caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Tucatinib DMBESUA Major Increased metabolism of Enzalutamide caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Palbociclib DMD7L94 Major Increased metabolism of Enzalutamide caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Alpelisib DMEXMYK Major Increased metabolism of Enzalutamide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Macitentan DMP79A1 Major Increased metabolism of Enzalutamide caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [30]
PF-04449913 DMSB068 Major Increased metabolism of Enzalutamide caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [31]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Enzalutamide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [32]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Enzalutamide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [20]
Intedanib DMSTA36 Moderate Increased metabolism of Enzalutamide caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [21]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Enzalutamide caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [27]
Osilodrostat DMIJC9X Major Increased metabolism of Enzalutamide caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [17]
MK-8228 DMOB58Q Moderate Decreased metabolism of Enzalutamide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [22]
Vortioxetine DM6F1PU Moderate Increased metabolism of Enzalutamide caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [33]
OPC-34712 DMHG57U Moderate Increased metabolism of Enzalutamide caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [34]
Empagliflozin DMRF9YK Moderate Accelerated clearance of Enzalutamide due to the transporter induction by Empagliflozin. Diabetes mellitus [5A10] [21]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Enzalutamide caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [25]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Enzalutamide and Deutetrabenazine. Dystonic disorder [8A02] [17]
Ingrezza DMVPLNC Major Increased metabolism of Enzalutamide caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [35]
Stiripentol DMMSDOY Major Increased metabolism of Enzalutamide caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Enzalutamide caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Cannabidiol DM0659E Moderate Increased metabolism of Enzalutamide caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [17]
Bay 80-6946 DMLOS5R Major Increased metabolism of Enzalutamide caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [36]
Tazemetostat DMWP1BH Major Increased metabolism of Enzalutamide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [37]
Ripretinib DM958QB Major Increased metabolism of Enzalutamide caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [38]
Avapritinib DMK2GZX Major Increased metabolism of Enzalutamide caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [17]
PSI-7977 DMLSUWZ Major Accelerated clearance of Enzalutamide due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [25]
Daclatasvir DMSFK9V Major Increased metabolism of Enzalutamide caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [17]
MK-1439 DM215WE Major Increased metabolism of Enzalutamide caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Fostemsavir DM50ILT Major Increased metabolism of Enzalutamide caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Cobicistat DM6L4H2 Major Increased metabolism of Enzalutamide caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Dolutegravir DMCZGRE Minor Increased metabolism of Enzalutamide caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [41]
Elvitegravir DMG9B1U Major Increased metabolism of Enzalutamide caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Aliskiren DM1BV7W Moderate Increased metabolism of Enzalutamide caused by Aliskiren mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [21]
Levamlodipine DM92S6N Major Increased metabolism of Enzalutamide caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [42]
Lesinurad DMUR64T Moderate Increased metabolism of Enzalutamide caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [43]
TP-434 DM5A31S Major Increased metabolism of Enzalutamide caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [44]
Suvorexant DM0E6S3 Major Increased metabolism of Enzalutamide caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Tasimelteon DMLOQ1V Major Increased metabolism of Enzalutamide caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [46]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Enzalutamide and Polyethylene glycol. Irritable bowel syndrome [DD91] [19]
Naloxegol DML0B41 Major Increased metabolism of Enzalutamide caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [17]
Pemigatinib DM819JF Major Increased metabolism of Enzalutamide caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [17]
Brigatinib DM7W94S Major Increased metabolism of Enzalutamide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [47]
Ceritinib DMB920Z Major Increased metabolism of Enzalutamide caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [48]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Enzalutamide caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [49]
PF-06463922 DMKM7EW Major Increased metabolism of Enzalutamide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [50]
Osimertinib DMRJLAT Major Increased metabolism of Enzalutamide caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [25]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Enzalutamide due to the transporter induction by BIBW 2992. Lung cancer [2C25] [51]
Pralsetinib DMWU0I2 Major Increased metabolism of Enzalutamide caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [52]
Capmatinib DMYCXKL Major Increased metabolism of Enzalutamide caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [53]
Selpercatinib DMZR15V Major Increased metabolism of Enzalutamide caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [17]
Artesunate DMR27C8 Moderate Accelerated clearance of Enzalutamide due to the transporter induction by Artesunate. Malaria [1F40-1F45] [21]
Idelalisib DM602WT Major Increased metabolism of Enzalutamide caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [54]
GDC-0199 DMH0QKA Major Increased metabolism of Enzalutamide caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [55]
IPI-145 DMWA24P Major Increased metabolism of Enzalutamide caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [56]
Acalabrutinib DM7GCVW Major Increased metabolism of Enzalutamide caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [57]
Ibrutinib DMHZCPO Major Increased metabolism of Enzalutamide caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [17]
Ponatinib DMYGJQO Moderate Increased metabolism of Enzalutamide caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [25]
Arry-162 DM1P6FR Moderate Decreased clearance of Enzalutamide due to the transporter inhibition by Arry-162. Melanoma [2C30] [25]
Trametinib DM2JGQ3 Moderate Accelerated clearance of Enzalutamide due to the transporter induction by Trametinib. Melanoma [2C30] [21]
LGX818 DMNQXV8 Major Increased metabolism of Enzalutamide caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [58]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Enzalutamide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [25]
Ubrogepant DM749I3 Major Increased metabolism of Enzalutamide caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [59]
Rimegepant DMHOAUG Major Increased metabolism of Enzalutamide caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [60]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Enzalutamide and Siponimod. Multiple sclerosis [8A40] [25]
Deflazacort DMV0RNS Major Increased metabolism of Enzalutamide caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [17]
Fedratinib DM4ZBK6 Major Increased metabolism of Enzalutamide caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [17]
Vorapaxar DMA16BR Major Increased metabolism of Enzalutamide caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [61]
Rolapitant DM8XP26 Major Increased metabolism of Enzalutamide caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [17]
Netupitant DMEKAYI Major Increased metabolism of Enzalutamide caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [25]
Entrectinib DMMPTLH Major Increased metabolism of Enzalutamide caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [62]
S-297995 DM26IH8 Major Increased metabolism of Enzalutamide caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [63]
Olaparib DM8QB1D Major Increased metabolism of Enzalutamide caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [25]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Enzalutamide and Rucaparib. Ovarian cancer [2C73] [17]
MK-4827 DMLYGH4 Moderate Accelerated clearance of Enzalutamide due to the transporter induction by MK-4827. Ovarian cancer [2C73] [64]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Enzalutamide and Triclabendazole. Parasitic worm infestation [1F90] [17]
Istradefylline DM20VSK Major Increased metabolism of Enzalutamide caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [65]
Abametapir DM2RX0I Moderate Decreased metabolism of Enzalutamide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [66]
Macimorelin DMQYJIR Moderate Increased metabolism of Enzalutamide caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [67]
Lefamulin DME6G97 Major Increased metabolism of Enzalutamide caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [68]
Selexipag DMAHSU0 Moderate Accelerated clearance of Enzalutamide due to the transporter induction by Selexipag. Pulmonary hypertension [BB01] [21]
Riociguat DMXBLMP Moderate Increased metabolism of Enzalutamide caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [69]
Upadacitinib DM32B5U Major Increased metabolism of Enzalutamide caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [70]
Voxelotor DMCS6M5 Major Increased metabolism of Enzalutamide caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [71]
LDE225 DMM9F25 Major Increased metabolism of Enzalutamide caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [72]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Enzalutamide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [17]
Larotrectinib DM26CQR Major Increased metabolism of Enzalutamide caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [25]
LEE011 DMMX75K Major Increased metabolism of Enzalutamide caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [73]
Pitolisant DM8RFNJ Major Increased metabolism of Enzalutamide caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [17]
Pomalidomide DMTGBAX Moderate Accelerated clearance of Enzalutamide due to the transporter induction by Pomalidomide. Systemic sclerosis [4A42] [74]
Fostamatinib DM6AUHV Major Increased metabolism of Enzalutamide caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [75]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Enzalutamide due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [76]
As-1670542 DMV05SW Major Increased metabolism of Enzalutamide caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [77]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Enzalutamide and Lenvatinib. Thyroid cancer [2D10] [17]
Elagolix DMB2C0E Moderate Increased metabolism of Enzalutamide caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [78]
Fluticasone DMGCSVF Moderate Increased metabolism of Enzalutamide caused by Fluticasone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [21]
Betrixaban DM2C4RF Moderate Accelerated clearance of Enzalutamide due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [79]
⏷ Show the Full List of 109 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Butylated hydroxytoluene E00336 31404 Antioxidant
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Carmellose sodium E00625 Not Available Disintegrant
Ferric oxide black E00522 16211978 Colorant
Gelatin E00630 Not Available Other agent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
Haematite red E00236 14833 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Sorbitan tristearate E00516 17800859 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Hypromellose acetate succinate E00696 Not Available Coating agent; Solubilizing agent; Modified-release agent;Film/membrane-forming agent
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Enzalutamide 40mg tablet 40mg Tablet Oral
Enzalutamide 80mg tablet 80mg Tablet Oral
Enzalutamide 40mg capsule 40mg Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
7 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9 Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
10 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
11 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
12 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
13 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
14 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
15 Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
16 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
19 Canadian Pharmacists Association.
20 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
21 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
22 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
23 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
24 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25 Cerner Multum, Inc. "Australian Product Information.".
26 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
27 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
28 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
29 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
30 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
31 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
33 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
34 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
35 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
36 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
37 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
38 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
39 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
40 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
41 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
42 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
43 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
44 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
45 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
46 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
47 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
48 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
49 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
50 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
52 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
53 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
55 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
56 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
57 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
59 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
60 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
61 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
62 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
63 Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
64 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
65 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
66 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
67 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
68 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
69 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
70 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
71 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
72 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
73 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
74 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
75 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
76 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
77 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
78 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
79 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]